

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


[illegible][illegible]

Examiner Signature	<i>Amoguel</i>	Date Considered	<i>03/18/2003</i>
-----------------------	----------------	--------------------	-------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**


[illegible]

Examiner Signature	13 L :	Date Considered	03/18/2007
-----------------------	--------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/717,101
Filing Date	November 19, 2003
First Named Inventor	Harold L. Atkins
Group Art Unit	1648
Examiner Name	Bao Q. Li
Attorney Docket Number	18013-C1

NON PATENT PUBLICATIONS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BL		Stuart, "Autologous Bone Marrow Transplantation for Leukemia", Seminars in Oncology, Vol. 20, No.5, Suppl 6, pages 40-54, October 1993.	
		Hammert, et al., "Purging marrow or peripheral blood stem cells for autografting", Current Opinion in Hematology, Vol. 4, pages 423-428, 1997.	
		Schneidkraut, et al., "The Contribution of Animal Models to the Development of Treatments for Hematologic Recovery Following Myeloablative Therapy: A Review", Journal of Hematotherapy, Vol. 5, pages 631-646, 1996.	
		Rummel, et al., "Future Paradigm for Autologous Bone Marrow Transplantation: Tumor Purging and Ex Vivo Production of Normal Stem and Progenitor Cells", Journal of Hematotherapy, Vol. 3, pages 213-218, 1994.	
		Kvalheim, et al., "Purging of Tumor Cells from Leukapheresis Products: Experimental and Clinical Aspects", Journal of Hematotherapy, Vol. 5, pages 427-436, 1996.	
		Bird, et al., "4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non- Hodgkin's lymphoma patients at high risk of bone marrow involvement", Bone Marrow Transplantation Vol. 18, pages 309-313, 1996.	
		Hammert, et al., "Purging autologous bone marrow with monoclonal antibodies for transplantation in acute myelogenous leukemia", Blood Reviews, Vol. 11, pages 80-90, 1997.	
		Villeneuve, "Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasia with rhodamine derivatives", Biotechnol. Appl. Biochem., Vol. 30, pages 1-17, 1999.	
		Hirai, et al., "Adenovirus p53 Purging for Human Breast Cancer Stem Cell Products", Acta Haematol, Vol. 101, pages 97-105, 1999.	
		Marini, et al. "Purging of Contaminating Breast Cancer Cells from Hematopoietic Stem Cell Grafts by Adenoviral GAL-TEK Gene Therapy and Magnetic Antibody Cell Separation", Clinical Cancer Research, Vol. 5, pages 1557-1568, June 1999.	
		Damon, et al., "Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment of containing mitoxantrone for acute myelogenous leukemia", Bone Marrow Transplantation, Vol. 17, pages 93-99, 1996.	

Examiner
Signature

BLi

Date

Considered

8/18/2005

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**RECEIVED
CENTRAL FAX CENTER**

MAR-18-2005 14:45

PRONEURON

240 683 3794

P.05

MAR 18 2005

PTO/S&O&B (08-03)

Approved for use through 07/31/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/717,101
		Filing Date	November 19, 2003
		First Named Inventor	Harold Atkins
		Art Unit	1648
		Examiner Name	Bao Q. Li
Sheet 1	of 1	Attorney Docket Number	18013-C1

DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BLi		U.S. Application Number 10/743,639, claims 1-2 and 5-7.	
BLi		U.S. Application Number 10/743,649, claims 1 and 4-6.	

Examiner Signature	<i>Baoqun Li</i>	Date Considered	03/18/2005
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.